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DMD #3244R 4
Caspofungin is a semi-synthetic, lipopeptide antifungal agent of the novel echinocandin class of compounds (Letscher-Bru and Herbrecht, 2003) . Its antifungal activity is mediated by inhibition of synthesis of β-(1,3) glucan, an essential component in the cell wall of target organisms. Caspofungin has demonstrated potent antifungal activity in vitro against Candida, and Aspergillus isolates (Bartizal et al., 1997) and in vivo efficacy in mouse models of disseminated aspergillosis, and candidiasis (Abruzzo et al., 1997) . Caspofungin has been successfully used in the clinical arena for the treatment of esophageal candidiases, candidemia, and invasive aspergillosis (Arathoon et al., 2002; Mora-Duarte et al., 2002; Koss et al., 2002) . More recently, caspofungin has also been used as empirical anti-fungal therapy for patients with persistent fever and neutropenia (Walsh et al., 2004) . Due to its high molecular weight (1093 Da, Fig. 1 ) and unfavorable lipophilicity, oral bioavailability was extremely low in animals. This drug is, thus, used parenterally in humans. Following intravenous administration to healthy human volunteers, hepatic elimination appeared to be the main route of removal for the parent drug in that only 2% of unchanged drug was recovered in human urine (Stone et al., 2002) . The drug does not appear to be subject to metabolism by the cytochrome P450 system or other enzyme systems studied, and part of the metabolism is thought to be nonenzymatic hydrolysis (Sandhu et al., 2004; Stone et al., 2004a) . Overall, the metabolism of caspofungin is slow and most of the plasma area under the curve is associated with distributional phases. These physiochemical and observed pharmacokinetic properties associated with caspofungin suggest a role of hepatic transporter(s) as a key determinant of its elimination.
DMD #3244R
Since caspofungin is often utilized in the setting of severe life-threatening illnesses, a better understanding of the processes governing the disposition of this novel antifungal agent will enhance our knowledge of the potential caspofungin-drug interactions. In this study, a combination of in vivo animal models, in situ rat perfusion and in vitro heterologous transporter expression experiments were carried out to determine the relative extent and contribution of hepatic caspofungin uptake, and to show that the liver-specific transporter OATP1B1 (SLC21A6) may be a relevant transporter responsible for this uptake. DMD #3244R described previously. Radioactivity in the perfusate, bile, and liver homogenates was determined by liquid scintillation spectrometry. 3 H]caspofungin at 2 mg/kg, were re-perfused with a drug free 4% albumin solution for 1 hr to wash out the radioactivity associated with non-specific binding on cell membranes.
Adsorption of [
At the end of the wash, the remaining radioactivity in each liver was measured as described previously. and independent of drug concentrations from 0.1-100 µg/mL), plasma protein binding was determined by an ultracentrifugation method as described by Legg and Rowland (1987) . cells was carried out as described previously (Yamazaki et. al., 2001 [ 3 H]caspofungin (10 µg/mL) was recirculated through the liver in a 0.5% albumin solution, radioactivity in the perfusate declined in a biphasic fashion; a rapid decrease in the initial 5 minutes was followed by a very slow decline thereafter (Fig. 2) . The radioactivity retained in the liver at the end of a 60 min perfusion accounted for approximately 20% of the dose. The biliary excretion of radiolabeled drug was negligible within 1 hour of the perfusion. This suggests that the hepatic uptake of caspofungin is a 2-step process with a rapid initial phase, possibly due to the adsorption of the drug to the cell surface, followed by a slow transport process of the drug across the cell membrane (Xu et. al., 1996) . This biphasic trend is consistent with earlier observations from the tissue distribution study (Stone et al., 2004a) as well as with data presented in Table 1 indicating that the time course of hepatic uptake and elimination of
caspofungin is a slow process. Additional studies showed that the amount of radioactivity retained in the perfused rat liver was highly dependent on the unbound fraction in the perfusate, i.e., the higher the unbound fraction of caspofungin in the perfusate, the greater the amount of drug retained in the liver (Table 2 ). These findings support the cell surface hypothesis and also indicate that binding of caspofungin to albumin affects the drug available for hepatic uptake in that the initial adsorption step in this uptake depends upon the free fraction of caspofungin present in the perfusate.
Furthermore, the majority of the radioactivity in the liver (approximately 81%) following the initial rapid uptake process was removed by re-perfusing the liver with a drug-free, 4% albumin solution (Table 3) , presumably via competitive binding.
In additional experiments, the extent of radioactivity removed from the liver of rats dosed in vivo and subsequently perfused in situ with a drug-free, 4% albumin This article has not been copyedited and formatted. The final version may differ from this version. however, was removed from the liver at 24 hr post dose (Table 3) . Collectively, both in situ and in vivo results are consistent with the hypothesis that the hepatic uptake of caspofungin is a 2-step process involving an initial rapid binding of the drug to the cell surface that is followed by a slow mechanism of transport into the cell.
Caspofungin uptake is mediated by OATP1B1. In order to identify the proteins responsible for the hepatic uptake of caspofungin, transport experiments were performed in HeLa cells transiently transfected with a variety of cDNAs coding for members of human (OATP1A2, OATP2B1, OATP1B1, OATP4A1, and OATP1B3) and rat Oatp (Oatp1a1, 1a4, and 1a5), OAT (OAT1 and OAT3), OCT (OCT1 and 2), and NTCP families. When tested using a recombinant vaccinia system, a statistically significant difference in caspofungin uptake (up to 60 min) was not observed for any of the tested transporters, although a trend for greater cellular caspofungin accumulation was observed in cells expressing OATP1B1. As data from the perfused liver experiments suggested that the absolute amount of caspofungin taken up by the liver is relatively modest within 1 hour, we created and utilized Tet-on HeLa cells, a cell line expressing a tetracycline responsive nuclear receptor (Tet-on), to express OATP1B1 and OATP1B3. Unlike the recombinant vaccinia system, in which the system is optimized for assessing function during a defined time period after target gene transfection, the Tet-on HeLa cells can be used to assess transport function over long periods of time. Using this system, caspofungin uptake appeared to be enhanced in the Tet-on HeLa-OATP1B1 cell line, but not in Tet-on HeLa-OATP1B3 cells (Fig. 3) . The absolute amount transported, however, was modest for caspofungin even with the Tet-on HeLa cells. Thus, the affinity (K m ) for caspofungin uptake by OATP1B1 could not be accurately determined due to the low apparent transport efficiency.
Evaluation of caspofungin as a potential inhibitor of hepatic transporters. (Fig. 4) . Lovastatin, ursodeoxycholic acid, quinidine, and indomethacin were used as prototypical inhibitors of OATP1B1, NTCP, OCT1, and OAT1, respectively. These findings suggest that caspofungin may be a relatively weak inhibitor of multiple systems.
Inhibition of caspofungin on P-gp activity. The inhibitory effect of caspofungin on Pglycoprotein activity, as assessed using [ 
DISCUSSION
It is now increasingly recognized that structural complexities which add additional specificity or potency to a drug must be made with the recognition that such changes can lead to unexpected or unfavorable pharmacokinetic profile of the drug. Remarkable advances in our understanding of drug metabolizing enzymes, especially members of the cytochrome P450 (CYP) superfamily and their role in drug metabolism have resulted in the application of such knowledge to the design of drugs which are less likely to be dependent on certain CYP enzymes, or in some cases, bypass such metabolic steps.
However, it now appears that other processes, particularly drug transporters expressed in organs such as the liver, intestine and kidney can become a major pathway of drug disposition. In this study, the hepatic processes governing the uptake of caspofungin were characterized in vivo and in situ as well as by assessing the role of various transporters. Caspofungin is a semi-synthetic lipopolypeptide produced from a fermentation product of the fungus Glarea lozoyensis (Letscher-Bru and Herbrecht, 2003) . The drug molecule is large and structurally very complex (Fig. 1) . In addition, this drug is known to be water-soluble and to have poor oral bioavailability attributed to poor intestinal absorption which might be due to a combination of the large molecular weight and low lipophilicity (log P of -1.2) of the molecule. Preliminary pharmacokinetic studies in several animal species indicated that caspofungin possesses slow plasma clearance (Hajdu et. al., 1997) . The plasma clearance in humans was also observed to be low following single dose administration of compound (Stone et. al., 2002) . Disposition studies in human subjects indicated that the metabolism and excretion of caspofungin were very slow processes with little excretion or biotransformation taking This article has not been copyedited and formatted. The final version may differ from this version. Metabolism of caspofungin is thought to, partly, occur via non-enzymatic hydrolysis. The known metabolic pathways of caspofungin further support the involvement of these non-enzymatic processes (Balani et. al., 2000; Sandhu et al., 2004) .
The presence in the liver of a large percentage of the intravenous dose administered to rats (Table 1 and Stone et. al., 2004a) , indicates that the liver plays an integral role in the metabolism of caspofungin. However, since most of the metabolism of caspofungin is attributed to non-enzymatic hydrolytic processes, metabolism can likely occur in other tissues as well.
In this study we assessed the hepatic uptake of caspofungin in rats in vivo as well as by utilizing an in situ rat liver perfusion model. The results indicated that the hepatic uptake and elimination of caspofungin were slow processes (Table 1 and Fig. 2 ) and supported the pharmacokinetic and disposition profiles observed in vivo. This was also consistent with the observed long elimination half-life and time to reach steady-state for this drug in humans (Stone et. al., 2002) . Accordingly, we hypothesized that liverspecific transporter(s) might be involved in the hepatic uptake of this drug. To identify such a mechanism, cell lines with heterologous expression of various transporters were This article has not been copyedited and formatted. The final version may differ from this version. that a statistically significant uptake may not be observed since the efficiency of transport/cellular viability is known to decline over time (Blakely et al., 1991) .
In order to study relevant transport processes over prolonged periods of time, we then developed novel stable cell lines in which the gene of interest can be expressed in a regulated fashion. Specifically, a HeLa cell line expressing a tetracycline responsive nuclear receptor (Tet-on) was utilized to transduce the liver-specific OATP transporters, OATP1B1 and OATP1B3. These transporters were selected for use in the creation of a Tet-on-based stable cell line as these transporters are liver-specific and have
shown to possess broad substrate specificities including many drugs in clinical use. A number of laboratories, including ours, have shown that rifampin is transported by OATP1B1 and OATP1B3 (Tirona et al., 2003; Cui et al., 2001; Vavricka et al., 2002) .
Furthermore, rifampin appears to be a potent inhibitor of OATP1B1 (Tirona et al., 2003) .
Moreover, these data are consistent with the clinical studies which have shown that coadministration of rifampin to patients can acutely elevate caspofungin plasma levels (Stone et al., 2004b) . We have shown that the Tet-on-based OATP1B1 and OATP1B3
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 3) . However, due to the remarkably slow uptake process, we were not able to define relevant transport kinetics in terms of K m and Vmax. We then assessed a potential inhibitory effect of caspofungin on hepatic transporters such as OATP1B1, NTCP, OCT1, and renal organic anion transporter OAT1 and the well-known drug efflux pump, P-glycoprotein. Caspofungin appeared to be a modest inhibitor of the uptake transporters tested since at the higher concentration of 100 µM significant inhibition of OATP1B1, NTCP, OCT1 and OAT1 was observed (Fig. 4) . Similarly, caspofungin appeared to possess only a minimal inhibitory effect on P-gp (Fig. 5) . Since the plasma concentrations of caspofungin at clinically effective doses are 1 to 10 µM, a clinically relevant inhibition of the above-mentioned transporters appears unlikely assuming such in vitro data can be extrapolated to the in vivo situation. It is also possible, other processes such as endocytosis/pinocytosis may have a role in the hepatic uptake of this compound. However, observed clinical data showing a near two-fold increase in the plasma level of caspofungin after rifampin (a known OATP1B1 substrate and inhibitor)
co-administration suggest OATP1B1 may in fact be relevant to the in vivo disposition of this compound (Stone et al., 2004b) . Moreover, we are not aware of any studies that suggest rifampin can acutely inhibit a hepatic endocytotic pathway(s). We have noted that in human liver, OATP1B1 is highly expressed, and when assessed using Western analysis, the proportion of the highly glycosylated/larger molecular weight form of the This article has not been copyedited and formatted. The final version may differ from this version. transporter is far greater than that observed using in vitro expression systems (unpublished data). Therefore another possibility to account for the moderate and slow rate of uptake of caspofungin observed in this study could be due to the fact that currently available in vitro systems, while useful, underestimate the relative expression or function of OATP1B1 in vivo. However, if OATP1B1 is a major determinant of caspofungin hepatic uptake in vivo, a potential source of intersubject variability could result from coadministration of compounds that inhibit and/or induce OATP1B1 such as rifampin thereby affecting the pharmacokinetics of caspofungin and leading to possible drug-drug interactions. Another source of intersubject variability in the elimination of this compound may relate to single nucleotide polymorphisms (SNPs) in this transporter. We have reported recently that OATP1B1 has a number of SNPs (Tirona et al., 2001 ).
Furthermore, a number of functionally relevant SNPs in OATP1B1 were found to be relatively common among a population of European and African-American subjects (Tirona et al., 2001 ).
In conclusion, we demonstrate that the hepatic uptake of the novel antifungal agent caspofungin is a remarkably slow process, likely mediated, at least in part, by the uptake transporter OATP1B1. Accordingly, targeted in vitro and in vivo studies of drug transporters are likely to further enhance our understanding of the mechanisms of drug disposition and some of the observed drug-drug interactions.
This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. In situ perfusion 1 18.9 ± 2.0 3.7 ± 1.6
In vivo 0.5 8.4 ± 1.5 2.8 ± 0.4
In vivo 24 35.3 ± 3.2 28.6 ± 1.5 *Radioactivity recovered in the post wash perfusate was primarily present as parent compound.
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